Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

15 Aug 2025

Abstract excerpt

ABSTRACT: Although 3 commercial CD19-targeted chimeric antigen receptor (CAR) T-cell therapies are available for large B-cell lymphomas (LBCLs), no randomized clinical trials have compared their efficacy and safety. In this retrospective multicenter cohort study, we evaluated real-world clinical outcomes of patients with relapsed/refractory LBCL treated with axicabtagene ciloleucel (axi-cel), tisagenlecleucel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40815804
DOI: 10.1182/bloodadvances.2025016778

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaPMID 40815804Read ↗

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.Semantic proximity Read ↗

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experienceSemantic proximity Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Semantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity Read ↗

Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.